Immatics Biotechnologies GmbH
Headquarters country
Germany
Registry sponsor category
Industry
- Other names
- Immatics Biotechnologies GmbH
- Company name
- Immatics Biotechnologies GmbH
- Organisation type
- Industry
- Registered legal name
- Immatics Biotechnologies GmbH
- Registry sponsor category
- Industry
- Legal Entity Identifier (LEI)
- 52990000FO0PU2VM5X83
Related records
Trials (11)
- F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
- GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
- IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
- IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
- IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
- IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
- IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
- IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients
- Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
- Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
- Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme